中美(mei)福源成(cheng)立(li)于2015年(nian)1月26日(有(you)限公司(si)成(cheng)立(li)于2010年(nian)3月10日),公司(si)主(zhu)要(yao)從事醫藥產品、技(ji)(ji)術(shu)的開發以及轉讓自有(you)技(ji)(ji)術(shu)。
公(gong)(gong)(gong)(gong)司(si)(si)控股3個(ge)子(zi)公(gong)(gong)(gong)(gong)司(si)(si),分別是北京美福源生(sheng)(sheng)物(wu)(wu)醫藥(yao)(yao)科(ke)技(ji)(ji)有(you)限公(gong)(gong)(gong)(gong)司(si)(si)、天津林達生(sheng)(sheng)物(wu)(wu)科(ke)技(ji)(ji)有(you)限公(gong)(gong)(gong)(gong)司(si)(si)和(he)天津溥(pu)瀛生(sheng)(sheng)物(wu)(wu)技(ji)(ji)術有(you)限公(gong)(gong)(gong)(gong)司(si)(si)。這(zhe)3個(ge)子(zi)公(gong)(gong)(gong)(gong)司(si)(si)在(zai)股份公(gong)(gong)(gong)(gong)司(si)(si)中(zhong)分別承擔著(zhu)新(xin)藥(yao)(yao)研(yan)發的(de)不(bu)同(tong)研(yan)究內容和(he)階段(duan)性(xing)工作。公(gong)(gong)(gong)(gong)司(si)(si)與子(zi)公(gong)(gong)(gong)(gong)司(si)(si)一(yi)道以在(zai)中(zhong)國開(kai)展(zhan)原創(chuang)原研(yan)國家1類(lei)新(xin)藥(yao)(yao)的(de)臨床(chuang)前研(yan)究、臨床(chuang)試驗研(yan)究和(he)產業化作為公(gong)(gong)(gong)(gong)司(si)(si)的(de)主營業務。公(gong)(gong)(gong)(gong)司(si)(si)正在(zai)開(kai)展(zhan)中(zhong)的(de)原創(chuang)原研(yan)新(xin)藥(yao)(yao)均是以現有(you)重組蛋白質藥(yao)(yao)物(wu)(wu)的(de)長效化新(xin)藥(yao)(yao)研(yan)發為重點(dian)。公(gong)(gong)(gong)(gong)司(si)(si)與子(zi)公(gong)(gong)(gong)(gong)司(si)(si)共同(tong)擁(yong)有(you)這(zhe)個(ge)新(xin)藥(yao)(yao)研(yan)發技(ji)(ji)術平臺。
公(gong)司(si)還有合資公(gong)司(si):天津福盈生物(wu)制藥有限(xian)公(gong)司(si)。
公司于2015年7月30日在(zai)新(xin)三板掛牌成功;證(zheng)券(quan)簡稱:中美福源,證(zheng)券(quan)代(dai)碼:833178。